Atomo Diagnostics Ltd. (AU:AT1) has released an update.
Atomo Diagnostics Ltd. is set to increase its revenue through government-funded expansion of its HIV self-testing programs in Australia, with an anticipated $1.3 million from the national mail-out program and broader deployment of vending machines offering free HIV self-tests. The company, which provides the only HIV Self-Test on the Australian Register of Therapeutic Goods, sees this as a continuation of the shift towards decentralized public health services post-COVID-19, and expects a wider adoption of at-home testing for various infectious diseases.
For further insights into AU:AT1 stock, check out TipRanks’ Stock Analysis page.
